Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Launched by NATIONAL CANCER CENTER, KOREA · Jun 24, 2018
Trial Information
Current as of May 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called proton beam therapy for patients with liver metastasis, which means that colorectal cancer has spread to the liver. The therapy involves delivering targeted radiation five times a week for three weeks, with a total of 15 sessions. This trial aims to see if this specific type of radiation can effectively help patients who have limited liver tumors and may not be suitable for surgery due to other health conditions.
To participate in this trial, patients should have a confirmed diagnosis of colon cancer and only a few liver lesions, ideally less than two. It's important that there are no other widespread cancer issues that can't be controlled. Additionally, patients who are not candidates for surgery due to health problems like diabetes or heart disease may also qualify. If you or someone you know is facing similar challenges with colorectal cancer and liver metastasis, joining this trial could be a potential option to discuss with a healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions..
- • 2. If there is no other remote metastasis other than liver, or if there is, control is possible
- • 3. If there are less than 2 liver metastatic lesions
- • 4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.)
- Exclusion Criteria:
- • 1. Other histologic cancer other than adenocarcinoma of the colorectal
- • 2. Colorectal cancer without primary lesion resection
- • 3. If there is another remote metastasis and is not completely resected or regulated
- • 4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis
- • 5. Pregnancy and women under lactation
About National Cancer Center, Korea
The National Cancer Center Korea (NCC Korea) is a leading institution dedicated to cancer research, prevention, diagnosis, and treatment. As a prominent clinical trial sponsor, NCC Korea focuses on advancing innovative therapies and improving patient outcomes through rigorous scientific investigation and collaborative efforts. With a commitment to enhancing cancer care, the center conducts a wide range of clinical trials, fostering partnerships with academic institutions, healthcare providers, and industry stakeholders to translate research findings into effective clinical applications. Through its comprehensive approach, NCC Korea aims to contribute significantly to the global fight against cancer, ensuring that advancements in treatment are accessible to patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Goyang Si, Gyeonggi Do, Korea, Republic Of
Patients applied
Trial Officials
Dae Yong Kim, M.D.
Principal Investigator
National Cancer Center Korea(South Korea)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials